 Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Russell 3000 Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions accessed on June 19. 